Prefusion-specific glycoprotein B human antibodies protect against neonatal HSV-2 infection
Parastoo Amlashi(Vanderbilt University Medical Center), Ivelin Georgiev(Vanderbilt University Medical Center), Rachel H. Bonami(Vanderbilt University Medical Center), Lindsay E Bass(Vanderbilt University Medical Center), Perry T. Wasdin(Vanderbilt University Medical Center), Nicole V. Johnson(The University of Texas at Austin), Margaret E. Ackerman(Dartmouth College), Matthew D. Slein(The University of Texas at Austin), Alexandra A. Abu-Shmais(Vanderbilt University Medical Center), Nisali N. Mendis(Dartmouth College), Jason S McLellan(The University of Texas at Austin), Gwen Jordaan(Vanderbilt University Medical Center), David A Leib(Dartmouth College), JeongRyeol Kim(The University of Texas at Austin)
Cited by 1
Related Papers
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
|Science|2020|1.4k
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
|Science Translational Medicine|2021|503
Distinct Early Serological Signatures Track with SARS-CoV-2 Survival
|Immunity|2020|420
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma
|Proceedings of the National Academy of Sciences|2021|379